JP2008534541A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534541A5
JP2008534541A5 JP2008503415A JP2008503415A JP2008534541A5 JP 2008534541 A5 JP2008534541 A5 JP 2008534541A5 JP 2008503415 A JP2008503415 A JP 2008503415A JP 2008503415 A JP2008503415 A JP 2008503415A JP 2008534541 A5 JP2008534541 A5 JP 2008534541A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/002769 external-priority patent/WO2006103038A1/en
Publication of JP2008534541A publication Critical patent/JP2008534541A/ja
Publication of JP2008534541A5 publication Critical patent/JP2008534541A5/ja
Pending legal-status Critical Current

Links

JP2008503415A 2005-03-30 2006-03-27 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法 Pending JP2008534541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006939 2005-03-30
PCT/EP2006/002769 WO2006103038A1 (en) 2005-03-30 2006-03-27 Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture

Publications (2)

Publication Number Publication Date
JP2008534541A JP2008534541A (ja) 2008-08-28
JP2008534541A5 true JP2008534541A5 (https=) 2009-05-14

Family

ID=36545049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503415A Pending JP2008534541A (ja) 2005-03-30 2006-03-27 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法

Country Status (7)

Country Link
US (3) US7713961B2 (https=)
EP (1) EP1866034A1 (https=)
JP (1) JP2008534541A (https=)
AR (1) AR056862A1 (https=)
CA (1) CA2603404A1 (https=)
TW (1) TW200716152A (https=)
WO (1) WO2006103038A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
WO2010042796A1 (en) 2008-10-10 2010-04-15 Purdue Research Foundation Compounds for treatment of alzheimer's disease
US8394807B2 (en) 2008-11-20 2013-03-12 Purdue Research Foundation Quinazoline inhibitors of BACE 1 and methods of using
WO2010065861A2 (en) * 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
US20130059840A1 (en) * 2009-10-05 2013-03-07 Comentis, Inc. Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
WO2014036105A2 (en) * 2012-08-30 2014-03-06 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
CA3240346A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
MXPA03011399A (es) * 2001-06-08 2004-07-01 Elan Pharm Inc Metodos para tratar la enfermedad de alzheimer.
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
JP2005534614A (ja) * 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
AU2003299101A1 (en) * 2002-09-27 2004-04-19 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer's disease
CA2505098A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US20050090449A1 (en) 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
CN100430377C (zh) * 2003-06-30 2008-11-05 麦克公司 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂
WO2005110422A2 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050861A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
CA2617294A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618019A1 (en) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease

Similar Documents

Publication Publication Date Title
JP5387997B2 (ja) 血管の収縮または拡張による疾患治療剤
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
JP2008534541A5 (https=)
RU2008138649A (ru) Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний
CN102497862B (zh) 使用ck2调节剂的组合治疗
RU2007134380A (ru) Антибактериальные производные пиперидина
JP2012521428A5 (https=)
JP2006513265A5 (https=)
HUP0400851A2 (hu) Dihidro-benzo[b][1,4]diazepin-2-on-származékok, mint MGluR2 II antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
RU2003102389A (ru) Замещенные производные хиназолина и их применение в качестве ингибиторов
JP2007531744A5 (https=)
AR044981A1 (es) Combinacion de un inhibidor alosterico de metaloproteinasa de matriz 13 (mmp-13) y un ligando de un receptor alfa-2- delta
JP2006525226A5 (https=)
CA2514191A1 (en) Compound inhibiting dipeptidyl peptidase iv
JP2011502958A5 (https=)
CA2409741A1 (en) Tnf-.alpha. production inhibitors
JP2005526696A5 (https=)
JP2009541484A (ja) 5ht6モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ
JP2007517007A5 (https=)
PT1487424E (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii
JP2003505362A5 (https=)
RU2012146874A (ru) Производные пиразолопиридина
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
AU2008222890C1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds